Novo Nordisk Once-Weekly Insulin Hits Primary Goals In In Two Phase 3 Trials
Novo Nordisk A/S (NYSE:NVO) announced headline results from the ONWARDS 3 and ONWARDS 4 Phase 3a trials with once-weekly insulin icodec…
Rising Prices Drive Four Fold Increase In Exxon Mobil’s Q2 Earnings
Exxon Mobil Corp (NYSE:XOM) posted a Q2 profit of $4.14 per share, an almost four-fold increase over $1.10 a year ago…
Chevron Posts Bumper Q2 Profits Amid Rising Energy Prices, Lifts Share Buyback Guidance
Chevron Corporation (NYSE:CVX) posted a Q2 net profit of $11.6 billion, up 277% Y/Y, with an adjusted EPS of $5.82,…
AbbVie’s Q2 Sales Marginally Shy Of Wall Street Estimates, Confirms Annual Profit Outlook
AbbVie Inc (NYSE:ABBV) reports Q2 adjusted EPS of $3.37, up 11.2% Y/Y and beating the consensus of $3.33. Overall sales…
AstraZeneca Q2 Highlights: Profits Fall, COVID-19 Vaccine Sales Dip, Lifts Annual Sales Guidance
AstraZeneca Plc (NASDAQ:AZN) Q2 profits fell sharply on ballooning costs linked to its Alexion takeover. The net profit was down…
Bausch Health To Appeal Expected Court Decision On Xifaxan Patents
Yesterday, Bausch Health Companies Inc (NYSE: BHC) stock closed 50% lower after the reports on the order on patent litigation over Xifaxan (rifaximin).
Smith & Nephew Shares Fall On Lower Margins As Cost Headwinds Hit Q2 Profit
Smith & Nephew Plc (NYSE:SNN) reported Q2 revenue of $1.29 billion, up 1.2% on an underlying basis but down 3.1%…
Teladoc Health’s Revised Outlook ‘Implies More Downside’ According To This Analyst
Needham downgraded Teladoc Health Inc (NYSE:TDOC) to Hold following the company’s revised FY22 outlook, which now assumes the low end of…
Gilead’s Biktarvy Demonstrates High Efficacy In HIV/HBV Coinfection Patients
Gilead Sciences Inc (NASDAQ:GILD) announced results reinforcing Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) as a highly efficacious treatment option for HIV, including individuals with…
Why Did Fresenius Medical Care Shares Plunge To 52-Week Low
Shares of kidney dialysis provider Fresenius Medical Care AG & Co (NYSE:FMS) touched a 52-week low after the company cut its…